Review of senomorphic agents that modulate the senescence-associated secretory phenotype
This review describes senomorphic agents as a strategy that modulates the senescence-associated secretory phenotype without eliminating senescent cells, and it names missing biomarkers, tissue-specific delivery and long-term safety data as barriers to clinical use. [1]
Automatic summary · not editorially reviewed
The key findings
Senomorphic agents modulate the senescence-associated secretory phenotype without clearing senescent cells, unlike senolytics, which aim to eliminate them. [1]
The review groups senomorphic agents into old drugs with new uses and metabolic modulators, natural products and derivatives, and designed targeted synthetic inhibitors. [1]
Clinical translation is described as hindered by missing specific biomarkers, tissue-specific delivery systems and long-term safety data. [1]
The source at a glance
- Study type / format
- Review (abstract only)
- Population / context
- Senomorphic agents and cellular senescence as covered in a review
- Summary based on
- Study abstract
- Original publication
- July 24, 2026
Senomorphics versus senolytics in the review
The review contrasts two approaches to cellular senescence. Senolytics aim to eliminate senescent cells. Senomorphic agents instead modulate the senescence-associated secretory phenotype without clearing the cells, so their potential physiological functions are preserved. The review states that senescence mainly drives chronic inflammation and tissue dysfunction through this secretory phenotype.
Supporting source [1]
Three categories and named example agents
The review classifies senomorphic agents into three categories: old drugs with new uses and metabolic modulators, with metformin as an example; natural products and their derivatives, with urolithin A as an example; and designed targeted synthetic inhibitors, with ruxolitinib as an example. It describes multi-target mechanisms including inhibition of signaling pathways such as NF-κB, mTOR, JAK/STAT and cGAS-STING.
Supporting source [1]
Translational scope and stated barriers
The review examines translational potential in neurodegenerative diseases, cardiovascular ageing and osteoarthritis, and it highlights advantages of drug repurposing and of combining senomorphics with senolytics. It states that clinical translation remains hindered by the lack of specific biomarkers, tissue-specific delivery systems and long-term safety data. The review presents senomorphics as promising for healthy ageing while describing the move from preclinical models to clinical practice as still to be achieved.
Supporting source [1]
How to interpret this
This is an abstract of a review; the full text was not reviewed. The abstract reports no study design, sample, follow-up or outcome data, and the agents and mechanisms it names are presented as review content, not as demonstrated human benefits.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Kong Y, Zhang Q, Zhang J, Fu Q. · europepmc.org · July 24, 2026